1. SystemicAdministration of PRO051in Duchenne’s Muscular Dystrophy NathalieM. Goemans, M.D., Mar Tulinius, M.D., Ph.D.,Johanna T. van den Akker, Ph.D., Brigitte E. Burm, Ph.D., Peter F. Ekhart, M.Sc.,Niki Heuvelmans, TjadineHolling, Ph.D., Anneke A. Janson,Gerard J. Platenburg, M.Sc., Jessica A. Sipkens, M.Sc., J.M. Ad Sitsen, M.D., Ph.D.,Annemieke Aartsma-Rus, Ph.D., Gert-Jan B. van Ommen, Ph.D.,GunnarBuyse, M.D., Ph.D., NiklasDarin, M.D., Ph.D.,Jan J. Verschuuren, M.D., Ph.D., Giles V. Campion, M.D.,SjefJ. de Kimpe, Ph.D., and Judith C. van Deutekom, Ph.D María Antonia Velásquez Daniela Vásquez Medicina UPB 2011
29. CONCLUSIONS The method studied in this project is a new hope of recovery for the persons with Duchenne's Muscular Dystrophy It is an innovative method that though it is not the exit of the disease would provide a well-known improvement in the quality of life of these persons The therapy antisense using oligonucleotidesas the PRO051 it is very effective for the treatment of the patients with DMD, since these manage to block the expression of the defective gene of dystrofin, diminishing this way his effects The implementation of this constant treatment with PRO051 manages to increase the life expectation of the patients with DMD